ASX:BIT

Stock Analysis Report

Executive Summary

Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Biotron's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BIT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

17.3%

BIT

11.2%

AU Biotechs

13.4%

AU Market


1 Year Return

10.0%

BIT

55.2%

AU Biotechs

-18.8%

AU Market

Return vs Industry: BIT underperformed the Australian Biotechs industry which returned 55.2% over the past year.

Return vs Market: BIT exceeded the Australian Market which returned -18.8% over the past year.


Shareholder returns

BITIndustryMarket
7 Day17.3%11.2%13.4%
30 Day-26.7%-0.06%-20.7%
90 Day69.2%10.9%-24.4%
1 Year10.0%10.0%56.8%55.2%-15.2%-18.8%
3 Year182.5%144.4%147.5%139.1%-2.8%-15.9%
5 Year-32.2%-41.3%234.1%213.1%9.3%-15.3%

Price Volatility Vs. Market

How volatile is Biotron's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biotron undervalued compared to its fair value and its price relative to the market?

6.35x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BIT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BIT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BIT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BIT is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BIT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BIT is overvalued based on its PB Ratio (6.4x) compared to the AU Biotechs industry average (2.4x).


Next Steps

Future Growth

How is Biotron forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biotron has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Biotron performed over the past 5 years?

9.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BIT is currently unprofitable.

Growing Profit Margin: BIT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BIT is unprofitable, but has reduced losses over the past 5 years at a rate of 9% per year.

Accelerating Growth: Unable to compare BIT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.5%).


Return on Equity

High ROE: BIT has a negative Return on Equity (-40.74%), as it is currently unprofitable.


Next Steps

Financial Health

How is Biotron's financial position?


Financial Position Analysis

Short Term Liabilities: BIT's short term assets (A$8.7M) exceed its short term liabilities (A$378.9K).

Long Term Liabilities: BIT's short term assets (A$8.7M) exceed its long term liabilities (A$33.0K).


Debt to Equity History and Analysis

Debt Level: BIT is debt free.

Reducing Debt: BIT has not had any debt for past 5 years.


Balance Sheet

Inventory Level: BIT has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if BIT's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BIT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BIT has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 10.6% each year.


Next Steps

Dividend

What is Biotron's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BIT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.0yrs

Average board tenure


CEO

Michelle Miller

no data

Tenure

AU$351,260

Compensation

Dr. Michelle Miller, BSc., MSc., PhD, GCertAppFin (Finsia) serves as Chief Executive Officer of Biotron Ltd. and has been its Managing Director since June 2002. Dr. Miller served as Investment Manager at S ...


CEO Compensation Analysis

Compensation vs Market: Michelle's total compensation ($USD216.36K) is about average for companies of similar size in the Australian market ($USD245.57K).

Compensation vs Earnings: Michelle's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Michelle Miller
CEO, MD & Executive Directorno dataAU$351.26k0.45% A$262.0k
Michael Hoy
Independent Non Executive Chairman20yrsAU$77.04k1.33% A$775.9k
Robert Thomas
Independent & Non-Executive Director8yrsAU$41.09k0.52% A$304.0k
Susan Pond
Independent & Non-Executive Director8yrsAU$41.09k0.093% A$54.3k
Stephen Locarnini
Independent & Non-Executive Director1.42yrsAU$28.71k0.11% A$66.4k

8.0yrs

Average Tenure

Experienced Board: BIT's board of directors are considered experienced (8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BIT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.8%.


Top Shareholders

Company Information

Biotron Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biotron Limited
  • Ticker: BIT
  • Exchange: ASX
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$58.260m
  • Shares outstanding: 701.93m
  • Website: https://www.biotron.com.au

Number of Employees


Location

  • Biotron Limited
  • 56 Delhi Road
  • Suite 3.3
  • North Ryde
  • New South Wales
  • 2113
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BITNDASX (Australian Securities Exchange)NPV DFD 30/12/19 (EX-OPTION)AUAUDNo data
BITR.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 2001
BITASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJan 2001
BITCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJan 2001

Biography

Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, including Dengue, Zika, Influenza, Ebola, and SARs. Biotron Limited is based in North Ryde, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 10:35
End of Day Share Price2020/03/31 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.